NCT00352521View on ClinicalTrials.gov

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

December 31, 2006

Study Completion Date

July 31, 2009

Conditions

Brain and Central Nervous System Tumors

Interventions

DRUG

bevacizumab

DRUG

irinotecan

PROCEDURE

dynamic contrast-enhanced magnetic resonance imaging

Trial Locations (1)

27710

Duke Comprehensive Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Duke University

OTHER

NCT00352521 - Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma | Biotech Hunter | Biotech Hunter